FDA Approves CARBIDOPA AND LEVODOPA — Zydus Pharmaceuticals USA Inc.

Zydus Pharmaceuticals USA Inc. secured FDA approval for Carbidopa and Levodopa, providing a new oral generic option into the high-volume central nervous system (CNS) market. This approval impacts the Parkinson’s disease sector by expanding patient accessibility while increasing competitive pressure on existing trade names and generic pricing structures.